

Special Issue

Innovative Boron-Based Drug Delivery Systems

Message from the Guest Editors

This Special Issue aims to highlight cutting-edge advances in boron-based drug delivery, with BNCT as a core focus while also welcoming broader work on boron-containing drugs and boron-based nanomedicine, in line with the scope of *Pharmaceutics*. We invite studies that address the design, formulation, and in vitro/in vivo evaluation of boron agents, as well as translational research that bridges pharmaceutical technology with clinical or preclinical applications.

For this Special Issue, submissions of original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: (i) novel boron carriers for BNCT (small molecules, peptides, polymers, liposomes, nanoparticles, and hybrid systems); (ii) delivery optimization of approved or emerging boron drugs (e.g., benzoxaboroles and boronic acid-based therapeutics); (iii) formulation approaches advanced DDS platforms; (iv) boron-based nanomaterials for drug delivery and imaging; and (v) imaging, biodistribution analysis, dosimetry, and combination therapies integrating boron-based strategies with radiotherapy, chemotherapy, or immunotherapy.

Guest Editors

Dr. Makoto Shirakawa
Dr. Tomohiro Tanaka
Dr. Alexander Zaboronok

Deadline for manuscript submissions

31 August 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/266507

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).